A new procedure for speeding access to essential medicines in low and middle income countries (LMICs) has produced its first fruit after the Swiss regulator issued a marketing authorization for a drug from Ferring used in the prevention of uterine haemorrhage.
Ferring described the approval as a landmark. The company will now submit its dossier to national regulatory authorities (NRAs) in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?